Bluebird bio Inc

Bluebird bio — ASCO Analyst & Investor Webcast 2018

20 slides from Bluebird bio's conference presentation, Jun 4, 2018

  1. Slide 1: ASCO Analyst & Investor Webcast

    ASCO Analyst & Investor Webcast June 1, 2018 NASDAQ: BLUE June 1, 2018 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    These slides and the accompanying oral presentation contain forward-looking statements and information relating to bluebird bio, its product candidate bb2121 and oncology research and development plans. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “belie

  3. Slide 3: Welcome

    Welcome Nick Leschly, chief bluebird

  4. Slide 4: bluemojo: Making Hope A Reality

    ~ bluemojo Making Hope A Reality

  5. Slide 5: The Gene Therapy Company

    T H E G E N E T H E R A P Y P R O D U C T S C O M P A N Y LentiGlobin SCD Data-Driven Acceleration LentiGlobin TDT First Filing (2018) Lenti-D CALD First Filing (2019) Patient Impact ∞ bb2121 Multiple Myeloma First Filing (2019) Products on the Market 2+ Additional Programs in the Clinic 4+ Programs

  6. Slide 6: Key Questions for Today

    Key Questions for Today What more have we learned about efficacy and durability of bb2121 in this heavily pretreated patient population? What are the new learnings? BCMA expression? Dose response? Is the safety profile still manageable? Is the path to earlier lines progressing?

  7. Slide 7: CRB-401 Data Update

    CRB-401 Data Update David Davidson, M.D., chief medical officer

  8. Slide 8: Baseline Demographics and Clinical Characteristics

    Baseline Demographics and Clinical Characteristics Parameter Escalation (N=21) Expansion (N=22) Median (min, max) follow-up, d 345 (46, 638) 87 (29, 184) Median (min, max) age, y 58 (37, 74) 65 (44, 75) Male, n (%) 13 (62) 16 (73) Median (min, max) time since diagnosis, y 4 (1, 16) 6 (1, 36) ECOG PS

  9. Slide 9: Heavily Pretreated Patient Population

    Parameter Escalation (N=21) Expansion (N=22) Exposed Refractory Exposed Refractory Prior therapies, n (%) Bortezomib 21 (100) 14 (67) 22 (100) 16 (73) Carfilzomib 19 (91) 12 (57) 21 (96) 14 (64) Lenalidomide 21 (100) 19 (91) 22 (100) 18 (82) Pomalidomide 19 (91) 15 (71) 22 (100) 21 (96) Daratumumab

  10. Slide 10: Tumor Response: Dose-related and Independent of Myeloma BCMA Expression

    CR, complete response; mDOR, median duration of response; ORR, objective response rate; PD, progressive disease; PR, partial response; sCR, stringent CR; VGPR, very good partial response. Data cut-off: March 29, 2018. 1Patients with ≥2 months of response data or PD/death within <2 months. ORR is def

  11. Slide 11: Hitting the Mark for Progression Free Survival

    Data cut-off: March 29, 2018. Median and 95% CI from Kaplan-Meier estimate. NE, not estimable. 1PFS in dose escalation cohort. mPFS of 11.8 months at active doses (≥150 x 106 CAR+ T cells) in 18 subjects in dose escalation mPFS of 17.7 months in 16 responding subjects from all study cohorts who are

  12. Slide 12: CAR T Treatment-Emergent Adverse Events

    TEAE, n (%) Overall Grade ≥3 Cytokine release syndrome1 27 (63) 2 (5) Neurotoxicity2 14 (33) 1 (2) Neutropenia 35 (81) 34 (79) Thrombocytopenia 26 (61) 22 (51) Anemia 24 (56) 19 (44) Infection3 Overall First Month 26 (61) 10 (23) 9 (21) 2 (5) CAR T Treatment-Emergent Adverse Events All Infused Patie

  13. Slide 13: bb2121-MM-001: Registration-Enabling Trial (KarMMa)

    Relapsed and refractory MM ≥3 prior treatment regimens with ≥ 2 consecutive cycles each (unless PD was best response) Received prior IMiD®, PI and anti-CD38 Refractory (per IMWG) to last treatment regimen bb2121-MM-001: bb2121 Registration-Enabling Trial (KarMMa) Endpoints Primary: ORR Key Secondary

  14. Slide 14: Advancing bb2121 into Earlier Lines of Multiple Myeloma

    Advancing bb2121 into Earlier Lines of Multiple Myeloma Registration-enabling trial in late line open to enrollment Planned Ph III in 3rd line vs. Dara/Pom/dex Explore label expansion opportunity in 2nd line setting Opportunities for bb2121 in NDMM including high risk, TNE and TE vs. transplant Comp

  15. Slide 15: Closing

    Closing Nick Leschly, chief bluebird

  16. Slide 16: Response to Current Standard of Care in Late Line RRMM

    Response to Current Standard of Care in Late Line RRMM Chari, A. Blood 2017 43

  17. Slide 17: bb2121 Patient Case: Months in sCR

    bb2121 Patient Case: 21 Months in sCR General Information Age & Gender 52 year old Male Dose group 150x10^6 Tumor Burden High High Risk Cytogenetics (based on FISH) No Number of prior regimens 6 Initial diagnosis May, 2010 BCMA% (prescreen, baseline) 60, 75 VRD, Doxo VRD, M, ASCT K Pom bb2121 Durati

  18. Slide 18: Key Takeaways

    Key Takeaways Efficacy? Durability? BCMA? MRD? Safety? Path forward? 95.5% ORR in doses above 150M cells. 50% CR rate at doses above 150M cells. 11.8 months median PFS in dose-escalation active doses. 17.7 months median PFS in MRD(-) patients with response (escalation and expansion). Consistent resp

  19. Slide 19: Stay Tuned…

    Stay Tuned… *Celgene Responsibility, **Anticipated Clinical Data Updates EHA MM Encore data presentation TDT Updated data SCD Updated data EHA Conference Call: June 15, 8:00 am ET 2H** TDT First clinical data in TDT and β0/β0 genotypes TDT EMA filing MM First bb21217 clinical data CALD Updated data

  20. Slide 20: Q&A

    Q&A bluebirdbio’

bluebird bio — ASCO Analyst & Investor Webcast 2018 on 6ix